Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Astellas Pharma Inc.    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Astellas Pharma : Launches a 'Contact for Potential Acquisition of ' R&D Programs Section on its Corporate Website

11/26/2020 | 09:09am EST

Astellas Pharma Inc. ('Astellas') has launched a 'Contact for Potential Acquisition of Astellas' R&D programs' section on its corporate website.

This section was developed to recruit potential parties who wish to acquire Astellas' R&D programs that were terminated for strategic reasons.

Astellas has been working on the effective utilization of its assets from programs for which it has terminated R&D by considering the continuation of R&D that uses external resources and redevelopment for other indications. This endeavor is part of this effort, and the company is planning to post some of its terminated programs on the website successively to widely recruit potential parties. Through this, we hope to deliver new treatment options for patients suffering from diseases with high unmet medical needs.

Contact:

Tel: +81-3-3244-3000

(C) 2020 Electronic News Publishing, source ENP Newswire

All news about ASTELLAS PHARMA INC.
01/14ACTINIUM PHARMACEUTICALS : and Astellas Announce Research Collaboration Focused ..
AQ
01/06ASTELLAS PHARMA INC. : - FDA Accepts for Priority Review the New Drug Applicatio..
AQ
2020ASTELLAS PHARMA : FDA Lifts Clinical Hold for Audentes Therapeutics' AT132 Trial
MT
2020ASTELLAS PHARMA : Reports XOSPATA in Combination with Azacitidine Did Not Meet E..
AQ
2020ASTELLAS PHARMA : Supports Recommendations of Task Force on Climate-related Fina..
AQ
2020ASTELLAS PHARMA INC. : - Expansion of the Domestic Logistics Platform for Pharma..
AQ
2020VIATRIS : Astellas and Viatris Announce Termination of Co-promotion, Succession ..
AQ
2020Japan shares slip for third day; all eyes on U.S. stimulus debate
RE
2020Japanese shares slip back as investors look to U.S. stimulus debate
RE
2020Astellas Pharma, Viatris Pharmaceuticals Japan to End Joint Sales Promotion o..
MT
More news
Financials
Sales 2021 1 272 B 12 253 M 12 253 M
Net income 2021 181 B 1 744 M 1 744 M
Net cash 2021 440 B 4 239 M 4 239 M
P/E ratio 2021 17,0x
Yield 2021 2,50%
Capitalization 3 130 B 30 155 M 30 153 M
EV / Sales 2021 2,11x
EV / Sales 2022 1,93x
Nbr of Employees 15 883
Free-Float 99,2%
Chart ASTELLAS PHARMA INC.
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 2 268,18 JPY
Last Close Price 1 685,00 JPY
Spread / Highest target 114%
Spread / Average Target 34,6%
Spread / Lowest Target -2,08%
EPS Revisions
Managers and Directors
NameTitle
Kenji Yasukawa President, CEO & Representative Director
Yoshihiko Hatanaka Chairman
Naoki Okamura Representative Director & Vice President
Tomokazu Fujisawa Director
Hiroko Sakai Director
Sector and Competitors
1st jan.Capitalization (M$)
ASTELLAS PHARMA INC.5.71%30 155
JOHNSON & JOHNSON3.92%430 552
ROCHE HOLDING AG3.06%308 615
NOVARTIS AG2.73%220 726
MERCK & CO., INC.-1.00%204 882
PFIZER INC.-0.71%203 159